{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:00:45Z","timestamp":1793325645159,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00520-023-07978-y","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T09:02:07Z","timestamp":1691053327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prevalence and predictors of long-delayed (&gt;\u2009120\u00a0h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi Bellinda","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Baqri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaid","family":"Younus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Prsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"7978_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor C, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497\u2013503","journal-title":"Support Care Cancer"},{"issue":"4","key":"7978_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307\u201313","journal-title":"Support Care Cancer"},{"issue":"2","key":"7978_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00520-021-06606-x","volume":"30","author":"R Chow","year":"2022","unstructured":"Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH (2022) Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer 30(2):1015\u20131018","journal-title":"Support Care Cancer"},{"issue":"7","key":"7978_CR4","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29(7):3439\u20133459","journal-title":"Support Care Cancer"},{"issue":"5","key":"7978_CR5","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting\u2014a systematic review and meta-analysis. Support Care Cancer 28(5):2095\u20132103","journal-title":"Support Care Cancer"},{"issue":"8","key":"7978_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM et al (2018) Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26(8):2519\u20132549","journal-title":"Support Care Cancer"},{"issue":"28","key":"7978_CR7","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 35(28):3240\u20133261","journal-title":"J Clin Oncol"},{"key":"7978_CR8","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119\u2013v133","journal-title":"Ann Oncol"},{"issue":"10","key":"7978_CR9","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1002\/onco.13888","volume":"26","author":"L Zelek","year":"2021","unstructured":"Zelek L, Debourdeau P, Bourgeois H et al (2021) A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Oncologist 26(10):e1870\u2013e1879","journal-title":"Oncologist"},{"issue":"2","key":"7978_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2021","unstructured":"Hata A, Okamoto I, Inui N et al (2021) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40(2):180\u2013188","journal-title":"J Clin Oncol"},{"key":"7978_CR11","unstructured":"Higgins J, Morgan R, Rooney A et al (2022) Risk of Bias In Non-randomized Studies - of Exposure (ROBINS-E). https:\/\/www.riskofbias.info\/welcome\/robins-e-tool"},{"issue":"2","key":"7978_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/annonc\/mdg075","volume":"14","author":"MS Aapro","year":"2003","unstructured":"Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R (2003) A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14(2):291\u2013297","journal-title":"Ann Oncol"},{"issue":"42","key":"7978_CR13","first-page":"168","volume":"147","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, Van Der Wall E, Van Den Heuvel JJG, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Pharm Weekbl 147(42):168\u2013176","journal-title":"Pharm Weekbl"},{"issue":"3","key":"7978_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0885-3924(02)00543-2","volume":"24","author":"S B\u00f6rjeson","year":"2002","unstructured":"B\u00f6rjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G (2002) Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manag 24(3):345\u201358","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"7978_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"Y Baba","year":"2017","unstructured":"Baba Y, Baba H, Yamamoto S et al (2017) Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus 30(2):1\u20137","journal-title":"Dis Esophagus"},{"issue":"32","key":"7978_CR16","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.20.00871","volume":"38","author":"RD Naik","year":"2020","unstructured":"Naik RD, V S, Singh V, Pillai AS, Dhawan D, Bakhshi S (2020) Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol 38(32):3785\u201393","journal-title":"J Clin Oncol"},{"issue":"22","key":"7978_CR17","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1002\/cncr.28892","volume":"120","author":"DL Barton","year":"2014","unstructured":"Barton DL, Thanarajasingam G, Sloan JA et al (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120(22):3575\u20133583","journal-title":"Cancer"},{"issue":"10","key":"7978_CR18","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1093\/annonc\/mdx315","volume":"28","author":"P Bossi","year":"2017","unstructured":"Bossi P, Cortinovis D, Fatigoni S et al (2017) A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann Oncol 28(10):2547\u20132551","journal-title":"Ann Oncol"},{"issue":"6","key":"7978_CR19","first-page":"371","volume":"52","author":"KS Chow","year":"1999","unstructured":"Chow KS, Iceton S (1999) Evaluation of a diary card for tailoring antiemetic therapy for children with cancer. Can J Hosp Pharm 52(6):371\u2013377","journal-title":"Can J Hosp Pharm"},{"issue":"5","key":"7978_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-2125.1996.03268.x","volume":"41","author":"DT Chua","year":"1996","unstructured":"Chua DT, Sham JS, Au GK et al (1996) The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial. Br J Clin Pharmacol 41(5):403\u2013408","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"7978_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00432-020-03143-8","volume":"146","author":"KM Cabanillas Stanchi","year":"2020","unstructured":"Cabanillas Stanchi KM, Vek J, Schlegel P et al (2020) Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 146(4):1089\u20131100","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"7978_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/bjc.1998.244","volume":"77","author":"R de Wit","year":"1998","unstructured":"de Wit R, van den Berg H, Burghouts J et al (1998) Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 77(9):1487\u20131491","journal-title":"Br J Cancer"},{"issue":"11","key":"7978_CR23","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41409-020-0909-2","volume":"55","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R et al (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 55(11):2114\u20132120","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"7978_CR24","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1188\/04.ONF.E1-E8","volume":"31","author":"SL Dibble","year":"2004","unstructured":"Dibble SL, Casey K, Nussey B, Israel J, Luce J (2004) Chemotherapy-induced vomiting in women treated for breast cancer. Oncol Nurs Forum 31(1):E1-8","journal-title":"Oncol Nurs Forum"},{"issue":"2","key":"7978_CR25","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1188\/03.ONF.E40-E47","volume":"30","author":"SL Dibble","year":"2003","unstructured":"Dibble SL, Isreal J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30(2):E40\u2013E47","journal-title":"Oncol Nurs Forum"},{"issue":"4","key":"7978_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00002820-200507000-00002","volume":"28","author":"J Lee","year":"2005","unstructured":"Lee J, Dibble SL, Pickett M, Luce J (2005) Chemotherapy-induced nausea\/vomiting and functional status in women treated for breast cancer. Cancer Nurs 28(4):249\u2013255","journal-title":"Cancer Nurs"},{"issue":"6","key":"7978_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000227521","volume":"52","author":"M Franchi","year":"1995","unstructured":"Franchi M, Donadello N, Zanaboni F, Tusei A, Scorbati E (1995) Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women. Oncology 52(6):509\u201312","journal-title":"Oncology"},{"issue":"5","key":"7978_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3109\/02841869409083931","volume":"33","author":"A du Bois","year":"1994","unstructured":"du Bois A, Vach W, Thomssen C et al (1994) Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. Acta Oncol 33(5):531\u2013535","journal-title":"Acta Oncol"},{"issue":"6","key":"7978_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/cncr.31198","volume":"124","author":"LL Dupuis","year":"2018","unstructured":"Dupuis LL, Kelly KM, Krischer JP et al (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: a single-blinded, randomized controlled trial. Cancer 124(6):1188\u20131196","journal-title":"Cancer"},{"issue":"4","key":"7978_CR30","doi-asserted-by":"publisher","first-page":"e27584","DOI":"10.1002\/pbc.27584","volume":"66","author":"LL Dupuis","year":"2019","unstructured":"Dupuis LL, Tamura RN, Kelly KM et al (2019) Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer 66(4):e27584","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"7978_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s005200000221","volume":"9","author":"M Fujii","year":"2001","unstructured":"Fujii M, Ohno Y, Tokumaru Y et al (2001) Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer. Support Care Cancer 9(5):366\u2013371","journal-title":"Support Care Cancer"},{"issue":"1","key":"7978_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0959-8049(97)00367-5","volume":"34","author":"X Garcia-del-Muro","year":"1998","unstructured":"Garcia-del-Muro X, Vadell C, P\u00e9rez Manga G et al (1998) Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer 34(1):193\u2013195","journal-title":"Eur J Cancer"},{"issue":"Suppl 3","key":"7978_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/annonc\/4.suppl_3.S35","volume":"4","author":"M Gershanovich","year":"1993","unstructured":"Gershanovich M, Kolygin B, Pirgach N (1993) Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ann Oncol 4(Suppl 3):35\u201337","journal-title":"Ann Oncol"},{"issue":"11","key":"7978_CR34","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1002\/cncr.10516","volume":"94","author":"S Van Belle","year":"2002","unstructured":"Van Belle S, Lichinitser MR, Navari RM et al (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 94(11):3032\u20133041","journal-title":"Cancer"},{"issue":"1","key":"7978_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","volume":"10","author":"A Hata","year":"2022","unstructured":"Hata A, Shiraishi Y, Inui N et al (2022) Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE). Oncol Ther 10(1):253\u2013262","journal-title":"Oncol Ther"},{"issue":"2","key":"7978_CR36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00520-015-2856-9","volume":"24","author":"Y Ando","year":"2016","unstructured":"Ando Y, Hayashi T, Ito K et al (2016) Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy. Support Care Cancer 24(2):871\u2013878","journal-title":"Support Care Cancer"},{"issue":"1","key":"7978_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12885-021-07802-y","volume":"21","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K et al (2021) Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer 21(1):74","journal-title":"BMC Cancer"},{"issue":"2","key":"7978_CR38","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/cas.14757","volume":"112","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K et al (2021) 5HT(3) RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. Cancer Sci 112(2):744\u2013750","journal-title":"Cancer Sci"},{"issue":"9","key":"7978_CR39","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1007\/s00520-021-06061-8","volume":"29","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Mizuki F et al (2021) Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis. Support Care Cancer 29(9):5029\u20135035","journal-title":"Support Care Cancer"},{"issue":"1","key":"7978_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21873\/anticanres.13101","volume":"39","author":"M Shimokawa","year":"2019","unstructured":"Shimokawa M, Hayashi T, Kogawa T et al (2019) Evaluation of combination antiemetic therapy on CINV in patients with gynecologic cancer receiving TC chemotherapy. Anticancer Res 39(1):225\u2013230","journal-title":"Anticancer Res"},{"issue":"7","key":"7978_CR41","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.1996.499","volume":"74","author":"TJ Hursti","year":"1996","unstructured":"Hursti TJ, Avall-Lundqvist E, B\u00f6rjeson S et al (1996) Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Cancer 74(7):1114\u20131119","journal-title":"Br J Cancer"},{"issue":"2","key":"7978_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-015-0908-2","volume":"21","author":"H Iihara","year":"2016","unstructured":"Iihara H, Fujii H, Yoshimi C et al (2016) Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol 21(2):409\u2013418","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"7978_CR43","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7150\/jca.13637","volume":"7","author":"H Iihara","year":"2016","unstructured":"Iihara H, Ishihara M, Fujii H et al (2016) Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer 7(5):569\u2013575","journal-title":"J Cancer"},{"issue":"7","key":"7978_CR44","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00520-014-2179-2","volume":"22","author":"Y Ikari","year":"2014","unstructured":"Ikari Y, Ogata K, Nakashima Y et al (2014) Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer 22(7):1959\u201364","journal-title":"Support Care Cancer"},{"issue":"5","key":"7978_CR45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2354.2005.00608.x","volume":"14","author":"M Ikeda","year":"2005","unstructured":"Ikeda M, Yasui M, Fukunaga H et al (2005) Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11. Eur J Cancer Care (Engl) 14(5):435\u2013439","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"7","key":"7978_CR46","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s00520-020-05958-0","volume":"29","author":"Y Kunitomi","year":"2021","unstructured":"Kunitomi Y, Nakashima M, Seki T, Ide K, Kawakami K (2021) Intergenerational comparison of 5-HT(3)RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database. Support Care Cancer 29(7):3951\u20133959","journal-title":"Support Care Cancer"},{"issue":"3","key":"7978_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00000421-200006000-00009","volume":"23","author":"CC Liaw","year":"2000","unstructured":"Liaw CC, Wang CH, Chang HK, Kao CY, Huang JS (2000) Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron. Am J Clin Oncol 23(3):253\u2013257","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"7978_CR48","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00520-011-1345-z","volume":"20","author":"CE Wu","year":"2012","unstructured":"Wu CE, Liaw CC (2012) Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Support Care Cancer 20(10):2357\u20132361","journal-title":"Support Care Cancer"},{"issue":"4","key":"7978_CR49","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s12032-010-9608-y","volume":"28","author":"X Dong","year":"2011","unstructured":"Dong X, Huang J, Cao R, Liu L (2011) Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Med Oncol 28(4):1425\u20131429","journal-title":"Med Oncol"},{"issue":"8","key":"7978_CR50","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00277-022-04877-w","volume":"101","author":"P Ye","year":"2022","unstructured":"Ye P, Pei R, Wang T et al (2022) Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study. Ann Hematol 101(8):1835\u20131841","journal-title":"Ann Hematol"},{"issue":"2","key":"7978_CR51","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/annonc\/mdh047","volume":"15","author":"P Eisenberg","year":"2004","unstructured":"Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15(2):330\u2013337","journal-title":"Ann Oncol"},{"issue":"1","key":"7978_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s005200000156","volume":"9","author":"R Maisano","year":"2001","unstructured":"Maisano R, Spadaro P, Toscano G, Caristi N, Pergolizzi S, Salimbeni V (2001) Cisapride and dexamethasone in the prevention of delayed emesis after cisplatin administration. Support Care Cancer 9(1):61\u201364","journal-title":"Support Care Cancer"},{"key":"7978_CR53","doi-asserted-by":"publisher","unstructured":"Marx W, McCarthy AL, Ried K et al (2017) The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial. Nutrients 9(8):867. https:\/\/doi.org\/10.3390\/nu9080867","DOI":"10.3390\/nu9080867"},{"issue":"6","key":"7978_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12185-016-2089-9","volume":"104","author":"Y Miyata","year":"2016","unstructured":"Miyata Y, Yakushijin K, Inui Y et al (2016) A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen. Int J Hematol 104(6):682\u2013691","journal-title":"Int J Hematol"},{"issue":"4","key":"7978_CR55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1046\/j.1365-2354.2000.00220.x","volume":"9","author":"A Molassiotis","year":"2000","unstructured":"Molassiotis A (2000) A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting. Eur J Cancer Care (Engl) 9(4):230\u2013234","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"5","key":"7978_CR56","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Aapro M, Dicato M et al (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manag 47(5):839\u201348.e4","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"7978_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1046\/j.1365-2354.2002.00300.x","volume":"11","author":"A Molassiotis","year":"2002","unstructured":"Molassiotis A, Mok TS, Yam BM, Yung H (2002) An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy. Eur J Cancer Care (Engl) 11(2):108\u2013113","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"7978_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jpainsymman.2013.03.007","volume":"47","author":"A Molassiotis","year":"2014","unstructured":"Molassiotis A, Russell W, Hughes J et al (2014) The effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: a randomized controlled trial. J Pain Symptom Manag 47(1):12\u201325","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"7978_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00520-001-0321-4","volume":"10","author":"A Molassiotis","year":"2002","unstructured":"Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10(2):139\u2013145","journal-title":"Support Care Cancer"},{"issue":"4","key":"7978_CR60","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000011866","volume":"55","author":"K M\u00fcnstedt","year":"1998","unstructured":"M\u00fcnstedt K, Wunderlich I, Blauth-Eckmeyer E, Zygmunt M, Vahrson H (1998) Does dexamethasone enhance the efficacy of alizapride in cis-platinum-induced delayed vomiting and nausea? Oncology 55(4):293\u2013299","journal-title":"Oncology"},{"issue":"1","key":"7978_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12282-019-01001-1","volume":"27","author":"Y Naito","year":"2020","unstructured":"Naito Y, Kai Y, Ishikawa T et al (2020) Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer 27(1):122\u2013128","journal-title":"Breast Cancer"},{"issue":"9","key":"7978_CR62","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/oxfordjournals.annonc.a010798","volume":"7","author":"I Olver","year":"1996","unstructured":"Olver I, Paska W, Depierre A et al (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 7(9):945\u201352","journal-title":"Ann Oncol"},{"issue":"6","key":"7978_CR63","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","volume":"21","author":"IN Olver","year":"2013","unstructured":"Olver IN, Grimison P, Chatfield M et al (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21(6):1561\u20131568","journal-title":"Support Care Cancer"},{"issue":"2","key":"7978_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/A:1008247830641","volume":"8","author":"JL Pater","year":"1997","unstructured":"Pater JL, Lofters WS, Zee B et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8(2):181\u2013185","journal-title":"Ann Oncol"},{"issue":"6","key":"7978_CR65","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/BF01880642","volume":"4","author":"C Peterson","year":"1996","unstructured":"Peterson C, Hursti TJ, B\u00f6rjeson S et al (1996) Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer 4(6):440\u2013446","journal-title":"Support Care Cancer"},{"issue":"10","key":"7978_CR66","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/bjc.1998.277","volume":"77","author":"RT Poon","year":"1998","unstructured":"Poon RT, Chow LW (1998) Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. Br J Cancer 77(10):1683\u20131685","journal-title":"Br J Cancer"},{"issue":"3","key":"7978_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/NCC.0b013e3182281493","volume":"35","author":"C Rodgers","year":"2012","unstructured":"Rodgers C, Kollar D, Taylor O et al (2012) Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment. Cancer Nurs 35(3):203\u2013210","journal-title":"Cancer Nurs"},{"issue":"1","key":"7978_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000066522","volume":"64","author":"S Sagae","year":"2003","unstructured":"Sagae S, Ishioka S, Fukunaka N et al (2003) Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynecologic cancer. Oncology 64(1):46\u201353","journal-title":"Oncology"},{"key":"7978_CR69","doi-asserted-by":"publisher","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L et al (2016) The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract 2016:3439707. https:\/\/doi.org\/10.1155\/2016\/3439707","DOI":"10.1155\/2016\/3439707"},{"issue":"Suppl 3","key":"7978_CR70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/annonc\/4.suppl_3.S39","volume":"4","author":"B Sorbe","year":"1993","unstructured":"Sorbe B (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Ann Oncol 4(Suppl 3):39\u201342","journal-title":"Ann Oncol"},{"issue":"6","key":"7978_CR71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF00344055","volume":"2","author":"B Sorbe","year":"1994","unstructured":"Sorbe B, Andersson H, Schmidt M et al (1994) Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting\u2013the Nordic experience. Support Care Cancer 2(6):393\u2013399","journal-title":"Support Care Cancer"},{"issue":"5","key":"7978_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/0959-8049(94)90534-7","volume":"30A","author":"B Sorbe","year":"1994","unstructured":"Sorbe B, H\u00f6gberg T, Himmelmann A et al (1994) Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur J Cancer 30A(5):629\u2013634","journal-title":"Eur J Cancer"},{"issue":"5 Suppl 9","key":"7978_CR73","first-page":"20","volume":"21","author":"BG Sorbe","year":"1994","unstructured":"Sorbe BG (1994) Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Semin Oncol 21(5 Suppl 9):20\u201326","journal-title":"Semin Oncol"},{"issue":"5","key":"7978_CR74","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1022::AID-CNCR29>3.0.CO;2-8","volume":"83","author":"BG Sorbe","year":"1998","unstructured":"Sorbe BG, Berglind AM, Andersson H et al (1998) A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 83(5):1022\u20131032","journal-title":"Cancer"},{"issue":"2","key":"7978_CR75","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/1097-0142(19940115)73:2<445::AID-CNCR2820730233>3.0.CO;2-4","volume":"73","author":"BG Sorbe","year":"1994","unstructured":"Sorbe BG, H\u00f6gberg T, Glimelius B et al (1994) A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 73(2):445\u2013454","journal-title":"Cancer"},{"issue":"1","key":"7978_CR76","doi-asserted-by":"publisher","first-page":"23298","DOI":"10.1038\/s41598-021-02765-3","volume":"11","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Takeshita T, Sugawara M (2021) Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment. Sci Rep 11(1):23298","journal-title":"Sci Rep"},{"issue":"5","key":"7978_CR77","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20(5):855\u2013865","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"7978_CR78","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF00417481","volume":"2","author":"EH Tan","year":"1994","unstructured":"Tan EH, Ang PT, Khoo KS (1994) Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. Support Care Cancer 2(3):197\u2013200","journal-title":"Support Care Cancer"},{"issue":"7","key":"7978_CR79","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011\u20131015","journal-title":"Br J Cancer"},{"issue":"4","key":"7978_CR80","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3802\/jgo.2015.26.4.311","volume":"26","author":"S Fujiwara","year":"2015","unstructured":"Fujiwara S, Terai Y, Tsunetoh S, Sasaki H, Kanemura M, Ohmichi M (2015) Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. J Gynecol Oncol 26(4):311\u2013319","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"7978_CR81","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K et al (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17(9):584\u2013589","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"7978_CR82","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14656566.2017.1317746","volume":"18","author":"Y Tsuji","year":"2017","unstructured":"Tsuji Y, Baba H, Takeda K et al (2017) Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother 18(8):753\u2013758","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"7978_CR83","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.3802\/jgo.2017.28.e44","volume":"28","author":"S Ohnishi","year":"2017","unstructured":"Ohnishi S, Watari H, Kanno M et al (2017) Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). J Gynecol Oncol 28(5):e44","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"7978_CR84","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00432-021-03554-1","volume":"147","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zheng Y, Yang X et al (2021) Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan. China J Cancer Res Clin Oncol 147(9):2701\u20132708","journal-title":"China J Cancer Res Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07978-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T16:26:37Z","timestamp":1729873597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07978-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7978"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07978-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"505"}}